Grufity logoGrufity logo

ARVN

40.34USD+0.78(+1.97%)Market Closed

ARVINAS HOLDING COMPANY, LLC

Market Summary

USD40.34+0.78Market Closed
1.97%

ARVN Alerts

ARVN Stock Price

RSI Chart

Valuation

Market Cap

2.7B

Price/Earnings

-11.62

Price/Sales

29.73

Price/Cashflow

5.31

Price/Sales

Profitability

Return on Equity

-34.77%

Return on Assets

-16.57%

Fundamentals

Revenue

Revenue (TTM)

112.1M

Revenue Y/Y

226.34%

Revenue Q/Q

-3.19%

Earnings

Earnings (TTM)

-252.6M

Earnings Y/Y

-41.6%

Earnings Q/Q

5.43%

Price Action

52 Week Range

34.9083.40
(Low)(High)

Last 7 days

-21.4%

Last 30 days

-18.4%

Last 90 days

-8.8%

Trailing 12 Months

-48.4%

Financial Health

Current Ratio

5.78

Debt/Equity

0

Debt/Cashflow

510.07

Investor Care

Shares Dilution (1Y)

0.67%

Diluted EPS (TTM)

-4.77

Peers (Alternatives to ARVINAS HOLDING COMPANY)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
459.8B
96.0B
2.92% 12.79%
24
4.79
5.02% 7.14%
342.0B
29.2B
2.35% 41.31%
60.08
11.76
5.34% 1.02%
266.2B
99.7B
7.75% -0.16%
9.08
2.63
43.92% 53.21%
255.3B
57.2B
9.24% 35.23%
15.4
4.47
35.88% 197.59%
163.4B
46.7B
6.43% 43.81%
24.47
3.5
2.79% 223.53%
MID-CAP
5.5B
4.4B
-18.01% -13.37%
-46.93
1.26
1.80% 57.67%
SMALL-CAP
1.9B
628.4M
4.90% -64.68%
-4.08
3.1
64.35% -18.14%
1.9B
659.0M
1.88% 10.24%
32.36
2.95
16.78% -53.92%
1.5B
-
15.46% -69.17%
-0.54
1.95
-4.11% -144.36%
1.2B
112.7M
0.32% -34.93%
-10.75
7.76
-54.94% 40.20%
1.1B
3.1M
10.32% -57.54%
-3.57
108.75
-77.09% -12.24%
1.0B
23.5M
6.37% 30.82%
-12.31
166.87
243.57% -1.04%
945.9M
373.2M
-3.41% -23.70%
4.56
2.34
-0.39% -38.45%
283.2M
49.7M
-18.16% -56.10%
-8.71
5.67
28.95% 32.80%
68.8M
2.6B
-43.99% -88.43%
-0.03
0.02
-13.88% -4855.92%

Financials for ARVINAS HOLDING COMPANY

Income Statement (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Revenue23.1%11291654723
Operating Expenses12.7%362321279242207
  S&GA Expenses5.0%8379696255
  R&D Expenses15.3%279242210180152
Net Income-8.3%-252.60-233.15-213.45-191.00-179.53
Balance Sheet
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Assets-5.1%1,3351,4071,4881,5821,605
  Current Assets-5.2%1,3051,3761,4571,5531,576
    Cash Equivalents42.3%1339362108256
  Net PPE2.9%1414131312
Liabilities-3.1%713736765800787
  Current Liabilities2.7%245238238262183
  Long Term Debt0%11111
    LT Debt, Non Current0%11111
Shareholder's Equity-7.3%622671723782818
  Retained Earnings-8.1%-882.50-816.30-746.30-682.90-629.89
  Additional Paid-In Capital1.3%1,5291,5091,4881,4691,448
Accumulated Depreciation8.8%1514121110
Shares Outstanding0%5353535353
* denotes actual numbers (not divided by Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2022Q32022Q22022Q12021Q42021Q3
Cashflow From Operations-146.7%-238.05510541559566
  Share Based Compensation5.2%7269635748
Cashflow From Investing114.6%108-739.13-1,097.18-1,313.60-1,141.10
Cashflow From Financing-97.0%8274277279746

Risks

What is the probability of a big loss on ARVN?

95%


Probability that ARVINAS HOLDING COMPANY stock will be more than 20% underwater in next one year

94.5%


Probability that ARVINAS HOLDING COMPANY stock will be more than 30% underwater in next one year.

55.9%


Probability that ARVINAS HOLDING COMPANY stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does ARVN drawdown profile look like?

Y-axis is the maximum loss one would have experienced if ARVINAS HOLDING COMPANY was unfortunately bought at previous high price.

Returns

Cumulative Returns on ARVN

5.8%


3-Year Cumulative Returns

Which funds bought or sold ARVN recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2022-11-22
Capital Impact Advisors, LLC
-
-
117,000
426,000
0.42%
2022-11-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
-
-
98,000
2,585,000
-%
2022-11-21
FourThought Financial, LLC
-
-
-
4,000
-%
2022-11-17
CENTRAL TRUST Co
SOLD OFF
-100
-
-
-%
2022-11-17
M&T Bank Corp
-
-
-18,000
426,000
-%
2022-11-16
CAPTRUST FINANCIAL ADVISORS
SOLD OFF
-100
-5,000
-
-%
2022-11-15
NOMURA HOLDINGS INC
REDUCED
-63.22
-9,243,000
5,787,000
0.02%
2022-11-15
CONCOURSE FINANCIAL GROUP SECURITIES, INC.
SOLD OFF
-
-
-
-%
2022-11-15
BNP PARIBAS ARBITRAGE, SNC
ADDED
49.97
436,533
1,182,410
-%
2022-11-15
SeaCrest Wealth Management, LLC
SOLD OFF
-100
-57,000
-
-%

1–10 of 46

Latest Funds Activity

Are funds buying ARVN calls or puts?
Are funds bullish or bearish(Calls - Puts)?
No. of funds that own ARVN

ARVINAS HOLDING COMPANY News

24/7 Wall St.

Friday’s Top Analyst Upgrades and Downgrades: Analog Devices, Autodesk, Beyond Meat, CVS Health, Dick’s Sporting Goods, Medtronic, Riot Blockchain, Tesla, Yum! Brands and More.2 days ago

ARVN Fair Value

Recent SEC filings of ARVINAS HOLDING COMPANY

View All Filings
Date Filed Form Type Document
Nov 22, 2022
8-K
Current Report
Nov 22, 2022
8-K
Current Report
Nov 22, 2022
8-K
Current Report
Nov 09, 2022
8-K
Current Report
Nov 09, 2022
10-Q
Quarterly Report
Aug 22, 2022
4
Insider Trading
Aug 22, 2022
3
Insider Trading
Aug 19, 2022
8-K
Current Report

Latest Insider Trading transactions for ARVN

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2022-08-12
Peck Ronald
SOLD
-86,794.5
68.994
-1,258
Chief Medical Officer
2022-08-12
Peck Ronald
ACQUIRED
-
-
4,010
Chief Medical Officer
2022-08-12
Peck Ronald
SOLD
-68,994
54.8442
-1,258
Chief Medical Officer
2022-04-14
Morrison Briggs
ACQUIRED
259,008
16
16,188
-
2022-04-14
Morrison Briggs
SOLD
-1,392,620
66.4416
-20,960
-
2022-03-31
Taylor Ian
GIFTED
-
-
-3,000
Chief Scientific Officer
2022-03-11
Cassidy Sean A
ACQUIRED
240,000
16
15,000
Chief Financial Officer
2022-03-11
Cassidy Sean A
SOLD
-1,050,000
70
-15,000
Chief Financial Officer
2022-03-04
Taylor Ian
SOLD
-55,563.9
63.94
-869
Chief Scientific Officer

1–10 of 50

John G. Houston
280
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.

ARVN Income Statement

2022-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
shares in Millions
3 Months Ended9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
Condensed Consolidated Statements of Operations    
Revenue$ 30,300,000$ 9,300,000$ 85,800,000$ 20,400,000
Operating expenses:    
Research and development77,500,00040,600,000216,700,000118,500,000
General and administrative20,000,000.016,000,000.064,500,00042,800,000
Total operating expenses97,500,00056,600,000281,200,000161,300,000
Loss from operations(67,200,000)(47,300,000)(195,400,000)(140,900,000)
Other income (expenses)    
Other (expense) income, net(200,000)200,000(400,000)1,700,000
Interest income, net3,400,000300,0006,300,0001,200,000
Total other income3,200,000500,0005,900,0002,900,000
Net loss before income taxes(64,000,000.0)(46,800,000)(189,500,000)(138,000,000.0)
Income tax expense(2,200,000)0(10,100,000)0
Net loss$ (66,200,000)$ (46,800,000)$ (199,600,000)$ (138,000,000.0)
Net loss per common share, basic (in dollars per share)$ (1.24)$ (0.94)$ (3.76)$ (2.81)
Net loss per common share, diluted (in dollars per share)$ (1.24)$ (0.94)$ (3.76)$ (2.81)
Weighted average common shares outstanding, basic (in shares)53.249.853.149.1
Weighted average common shares outstanding, diluted (in shares)53.249.853.149.1
Condensed Consolidated Statements of Comprehensive Loss    
Net loss$ (66,200,000)$ (46,800,000)$ (199,600,000)$ (138,000,000.0)
Other comprehensive loss:    
Unrealized loss on available-for-sale securities(2,800,000)(100,000)(20,200,000)(1,200,000)
Comprehensive loss$ (69,000,000.0)$ (46,900,000)$ (219,800,000)$ (139,200,000)

ARVN Balance Sheet

2022-09-30
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Millions
Sep. 30, 2022
Dec. 31, 2021
Current assets:  
Cash and cash equivalents$ 132.6$ 108.3
Restricted cash5.54.5
Marketable securities1,138.11,394.3
Accounts receivable1.015.0
Other receivables5.810.7
Prepaid expenses and other current assets21.719.7
Total current assets1,304.71,552.5
Property, equipment and leasehold improvements, net14.012.7
Operating lease right of use assets4.83.9
Collaboration contract asset and other assets11.312.5
Total assets1,334.81,581.6
Current liabilities:  
Accounts payable and accrued liabilities49.754.4
Deferred revenue193.1206.2
Current portion of operating lease liability1.81.1
Total current liabilities244.6261.7
Deferred revenue464.6534.3
Long term debt1.01.0
Operating lease liability3.12.9
Total liabilities713.3799.9
Commitments and Contingencies
Stockholders’ equity:  
Common stock, $0.001 par value; 53.2 and 53.0 shares issued and outstanding as of September 30, 2022 and December 31, 2021, respectively0.10.0
Accumulated deficit(882.5)(682.9)
Additional paid-in capital1,528.71,469.2
Accumulated other comprehensive loss(24.8)(4.6)
Total stockholders’ equity621.5781.7
Total liabilities and stockholders’ equity$ 1,334.8$ 1,581.6